bluebird bio Inc BLUE Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--

Filings by filing date

Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jan 13, 2021 (filed on Jan 13, 2021)

Insider Name:

Obenshain Andrew

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	60 Binney St CAMBRIDGE MA 02142-1512
Tel:	1-410-9605022
Website:	www.bluebirdbio.com
IR:	See website

Key People

Daniel S. Lynch Independent Chairman of the Board	Nick Leschly President, Chief Executive Officer, Director	William D. Baird Chief Financial Officer
Jason F Cole Chief Operating Officer and Legal Officer, Secretary	Katy Burnett Interim Principal Accounting Officer	Philip D. Gregory Chief Scientific Officer
David M. Davidson Chief Medical Officer	Alison C. Finger Chief Commercial Officer	Joanne M. Smith-Farrell Chief Business Officer

Business Overview

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Financial Overview

For the nine months ended 30 September 2020,bluebird bio Inc revenues increased from $34.7M to $240M.Net loss decreased 26% to $418.8M. Revenues reflectCollaborative arrangement revenue increase from $29.3M to$114.4M, Royalty and other revenue increase from $5.4M to$17.1M. Lower net loss reflects Change in fair value ofcontingent consi decrease from $1.3M (expense) to $5.6M(income).

Employees:	1,171 as of Sep 30, 2020

Reporting Currency:	U.S. Dollars
Enterprise value:	$2,211M as of Sep 30, 2020
Annual revenue (TTM):	$250.02M as of Sep 30, 2020
EBITDA (TTM):	-$634.32M as of Sep 30, 2020
Net annual income (TTM):	-$642.17M as of Sep 30, 2020
Free cash flow (TTM):	-$508.62M as of Sep 30, 2020
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	66,373,320 as of Oct 30, 2020
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

bluebird bio Inc (OQ:BLUE)